Clinical Biomarkers Global Market Report 2024

The clinical biomarkers market size has grown rapidly in recent years. It will grow from $27.66 billion in 2023 to $30.59 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The expansion observed in the historical period can be attributed to the increased prevalence of chronic diseases, a focus on personalized medicine and targeted therapies, advancements in drug development and clinical trials, as well as regulatory support and funding.

The clinical biomarkers market size is expected to see rapid growth in the next few years. It will grow to $46.11 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The anticipated growth in the forecast period can be attributed to the expansion of companion diagnostics, a heightened focus on early diagnosis and disease prevention, increasing applications in precision oncology and neurodegenerative diseases, and the growing prevalence of infectious diseases. Major trends in the forecast period include AI-powered biomarker discovery, integration of machine learning, multi-omics integration, technological innovations, and partnerships among key players.

The anticipated increase in cancer prevalence is set to drive the growth of the clinical biomarker market in the future. Cancer refers to a group of disorders characterized by the uncontrolled growth and division of abnormal cells, posing the potential to invade and harm healthy bodily tissues. Clinical biomarkers play a pivotal role in cancer prevention by facilitating early detection, risk assessment, and monitoring of individuals at a high risk of developing cancer. For example, as of May 2021, the National Library of Medicine reports a projected global cancer burden of 28.4 million cases in 2040, reflecting a 47% increase from 2020. Consequently, the high prevalence of cancer serves as a catalyst for the growth of the clinical biomarker market.

The expected rise in the aging population is poised to contribute to the growth of the clinical biomarker market. An aging population signifies a demographic shift marked by an increasing proportion of elderly individuals within a society over time. The global aging population is linked to a heightened prevalence of age-related diseases, necessitating biomarkers to enhance early diagnosis and disease management. As of October 2022, the World Health Organization forecasts that by 2030, one out of every six individuals globally will be 60 years old or older. During this period, the population aged 60 and over is projected to rise from 1 billion in 2020 to 1.4 billion. Furthermore, by 2050, the global population of individuals aged 60 and older is expected to double, reaching 2.1 billion. Hence, the increasing aging population is a significant driver of the clinical biomarker market.

Technological advancements emerge as a prominent trend gaining traction in the clinical biomarker market, with major companies focusing on developing innovative technologies to maintain their market positions. For instance, in June 2023, Veravas Inc., a US-based manufacturer of medicinal products for enhancing laboratory medicine, introduced the VeraBIND (Biomarker Isolation and N-enrichment for Detection) technology. This technology offers a uniquely innovative and comprehensive approach to enhance the precision of biomarker identification, reducing the likelihood of false positive or negative results across various sample types. The implementation of VeraBIND in clinical laboratories can improve diagnostic procedures, aiding in early disease detection and enabling prompt, focused interventions. Additionally, VeraBIND facilitates quicker assay creation, ensuring precision and consistency in studies, clinical trials, and diagnostic screenings.

Major companies in the clinical biomarker market are directing their efforts toward developing innovative solutions, including biomarker blood tests. Biomarker blood tests involve assessing specific biomolecules present in the blood to provide information about various physiological or pathological conditions in the body. For instance, in July 2023, Quanterix Corporation, a US-based ultra-sensitive digital immunoassay platform developing company, introduced the 'LucentAD.' This biomarker blood test is designed to assist in assessing patients exhibiting cognitive symptoms consistent with the initial indications of Alzheimer's disease (AD). LucentAD utilizes the extensively researched Simoa p-Tau 181 assay, which has undergone thorough examination in both large longitudinal and cross-sectional cohorts.

In June 2021, NeoGenomics Laboratories, a US-based testing laboratory company, completed the acquisition of Inivata for $390 million. Through this acquisition, NeoGenomics Laboratories aims to bolster its competitive advantage and increase its market share in the clinical biomarker industry. Inivata is a UK-based biotechnology company offering liquid biopsies.

Major companies operating in the clinical biomarkers market report are Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., Epigenomics AG, Grifols S.A., Illumina Inc., BioMerieux SA., Charles River Laboratories International Inc., PerkinElmer Inc., Sartorius AG, Sysmex Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Luminex Corporation, Veracyte Inc., Centogene N.V., NanoString Technologies Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Siemens Healthcare Private Limited.

North America was the largest region in the clinical biomakers market in 2023. The regions covered in the clinical biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The main components of clinical biomarkers are products and services. Products in the context of clinical biomarkers are items sold to meet customer needs or desires, whether physical or intangible, and they are utilized to aid in the diagnosis of diseases and conditions. Various technologies are employed in clinical biomarkers, including next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), and others. Clinical biomarkers cover a range of clinical areas, including cancer biomarkers, cardiac biomarkers, neurological biomarkers, infectious disease biomarkers, immunological biomarkers, non-invasive prenatal testing, and others. These biomarkers find applications in clinical diagnostics and translational research and are utilized by various end-users such as contract research organizations (CROs), research and academic laboratories, biopharmaceutical and biotech companies, diagnostic centers, and others.

The clinical biomarkers market research report is one of a series of new reports that provides clinical biomarkers market statistics, including clinical biomarkers industry global market size, regional shares, competitors with a clinical biomarkers market share, detailed clinical biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the clinical biomarkers industry. This clinical biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical biomarkers market consists of revenues earned by entities by providing services such as biomarker assay development, biomarker testing, and biomarker data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The clinical biomarkers market also includes sales of immunoassay kits, point-of-care testing devices, and genetic testing panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.